Table 4.

Individual responses of total IgG or IgG subclasses after influenza and pneumococcal polysaccharide immunization

Patients	Total IgG	IgG1	IgG2	IgG3	IgG4	Total IgG	IgG1	IgG2	IgG3	IgG4	Previous RTX
Influenza						P23
Pre-RTX
1	176	289	99	125	117	152	95	105	110	115	1
2 a	94	86	98	89	74	102	454	534	203	117	no
3 a	163	128	110	112	111	204	262	107	95	115	no
4 a	154	292	198	178	108	335	77	167	129	148	no
5 a	132	368	99	121	123	217	246	458	128	113	no
Post-RTX
1a	139	202	123	116	153	151	83	85	95	102	no
2	126	260	133	136	158	110	103	104	95	101	2
3	109	93	115	110	107	107	143	105	107	116	no
4	100	97	89	102	91	102	104	98	111	112	no
5a	115	89	72	100	96	93	87	211	112	108	no
6a	85	93	76	87	102	88	82	187	96	107	3
7	98	82	94	96	97	107	95	94	98	94	no
8	103	99	86	124	113	95	233	257	126	117	no
9a	104	102	115	91	103	126	92	105	92	98	1
10	127	222	115	160	170	104	159	248	175	206	2
11a	134	157	110	119	109	122	167	140	125	144	no
Controls
1	117	95	84	113	108	213	91	171	89	83	no
2a	191	252	96	125	127	115	897	521	235	278	no
3	100	157	100	50	105	139	137	178	109	95	no
4	96	145	97	105	113	136	467	216	159	137	no
5	121	205	101	191	126	105	114	112	107	111	no
6	116	124	123	108	119	97	154	136	151	112	no
7	113	123	179	111	111	71	316	259	120	122	no
8	174	234	127	146	121	161	167	140	108	105	no
9	97	98	72	144	123	111	65	84	114	101	no
10	99	142	116	129	124	194	271	122	132	889	no

^aPrednisolone, 2.5-10 mg/day.

Controls, RA patients never treated with RTX; P23, pneumococcal polysaccharide vaccine 23; pre-RTX group, RA patients treated with RTX 6 days after vaccination; post-RTX group, RA patients treated with RTX 6 months before vaccination; RTX, rituximab.

The levels of vaccine-specific antibodies at day 0 were taken as 100%. On day 21, the mean increase of antibody levels in the control group was 110%. This value indicated the cutoff for vaccination response in the RTX-treated patients.

Bold numbers and gray boxes indicate levels equal to or greater than the cutoff level (110%).